GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CureVac NV (NAS:CVAC) » Definitions » Price-to-Owner-Earnings

CureVac NV (CureVac NV) Price-to-Owner-Earnings : (As of Jun. 08, 2024)


View and export this data going back to 2020. Start your Free Trial

What is CureVac NV Price-to-Owner-Earnings?

As of today (2024-06-08), CureVac NV's share price is $4.49. CureVac NV does not have enough data to calculate Owner Earnings per Share (TTM), so as pPrice-to-Owner-Earnings.


The historical rank and industry rank for CureVac NV's Price-to-Owner-Earnings or its related term are showing as below:


CVAC's Price-to-Owner-Earnings is not ranked *
in the Biotechnology industry.
Industry Median: 33.7
* Ranked among companies with meaningful Price-to-Owner-Earnings only.

As of today (2024-06-08), CureVac NV's share price is $4.49. CureVac NV's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was $-1.32. Therefore, CureVac NV's PE Ratio for today is At Loss.

As of today (2024-06-08), CureVac NV's share price is $4.49. CureVac NV's EPS without NRI for the trailing twelve months (TTM) ended in was $-1.33. Therefore, CureVac NV's PE Ratio without NRI for today is At Loss.


CureVac NV Price-to-Owner-Earnings Historical Data

The historical data trend for CureVac NV's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CureVac NV Price-to-Owner-Earnings Chart

CureVac NV Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Owner-Earnings
Get a 7-Day Free Trial - - - - -

CureVac NV Quarterly Data
Mar19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Price-to-Owner-Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of CureVac NV's Price-to-Owner-Earnings

For the Biotechnology subindustry, CureVac NV's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


CureVac NV's Price-to-Owner-Earnings Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CureVac NV's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where CureVac NV's Price-to-Owner-Earnings falls into.



CureVac NV Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

CureVac NV's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=4.49/-1.85
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


CureVac NV  (NAS:CVAC) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


CureVac NV Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of CureVac NV's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


CureVac NV (CureVac NV) Business Description

Address
Friedrich-Miescher-Strasse 15, Tubingen, BW, DEU, 72076
CureVac is a biopharmaceutical company headquartered in Germany that is developing vaccines and therapies using messenger ribonucleic acid (mRNA). The company was founded in 2000 and had its initial public offering in August 2020. CureVac is collaborating with GlaxoSmithKline to develop a second-generation COVID-19 vaccine. CureVac's first attempt to develop a COVID-19 vaccine did not have sufficient efficacy data, and its trials were discontinued in October 2021. The company's other pipeline candidates include mRNA vaccines for influenza, rabies, and malaria. Additionally, CureVac is in the early stages of development for oncology and molecular therapies spanning tumors, liver, ocular, and lung diseases.

CureVac NV (CureVac NV) Headlines